- The Blood Test Revolution Driving These Three Stocks Investor’s Business Daily
- Circulating Tumor DNA Test May Help Predict Melanoma Recurrence Genetic Engineering and Biotechnology Current-News-Report
- New strategy may enable cancer monitoring from blood tests alone Medical Xpress
- Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, r The Lancet
- Blood Test Can Predict Melanoma Recurrence Tribune Ledger Current-News-Report
